DIRS.INFO The most relevant business & tech news

☆ These 4 stocks report quarterly results next week. Here's what we hope to see
▼ + stars: | 2023-11-04 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

The major averages rebounded strongly this week as quarterly earnings came in largely better than expected and interest rates fell on softer economic data. The Dow Jones Industrial Average rose more than 5% for its best week since October 2022. The big theme next week is earnings and the four portfolio companies delivering their quarterly results. Here's the full rundown of all the important domestic data in the week ahead as we consider a number areas of our portfolio for trades next week. ET: Treasury budget statement for October (See here for a full list of the stocks in Jim Cramer's Charitable Trust.)

Persons: FactSet, we'll, Hulu —, Krystal, Horton, Zimmer, LEV, Armour, Ralph Lauren Corporation, CRON, Patterson, Walt Disney, MARA, Ginkgo, FREYR Battery, FREY, Arcelor Mittal, Wynn, Jim Cramer's, Jim Cramer, Jim Organizations: Dow Jones, Nasdaq, ISM, Services, Coterra Energy, Emerson Electric, Wall, National Instruments, Disney, Hulu, CNBC, Comcast, ESPN —, Wynn Resorts, WYNN, Asia that's, Wynn, Wynn's, Wynn Interactive, United, Brookfield Asset Management, Axsome Therapeutics, Network Corporation, Krystal Biotech, Ceragon Networks, Kosmos Energy Ltd, TreeHouse Foods Inc, Air Lease Corporation, Inc, Eversource Energy, Fennec Pharmaceuticals Inc, Graham Corporation, Aereas Inteligentes, Hilton, Energy, Realty Income Corp, Semiconductors, Vertex Pharmaceuticals Inc, Clover Health, Contura Energy, Diamondback Energy, FS KKR Capital Corp, Celanese Corp, Eos Energy Enterprises, Goodyear Tire & Rubber Company, WEN, Pall Corp, TransMedics, Emerson, Uber Technologies, Holdings, Melco Resorts, Entertainment, Zimmer Biomet Holdings, ACM Research, Lion Electric Company, Emerson Electric Co, Vertex Energy, Waters Corp, Air Products & Chemicals, Esperion Therapeutics, Fidelity National Information Services Inc, Bowlero Corp, Hotels, KKR, Co, Devon Energy Corp, Occidental Petroleum Corp, Dutch Bros Inc, Gilead Sciences, ContextLogic Inc, Akamai Technologies, Viatris Inc, Technologies, Corsair, Enovix Corporation, eBay, EBAY, DaVita Inc, Pan American Silver Corp, Roblox Corporation, Fisker Inc, Warner Bros ., Nuvei Corporation, Farms, Akebia Therapeutics, Biogen Inc, 3D Systems Corporation, Gray Television Inc, BlackSky Technology Inc, Cronos, EVgo Inc, Lumentum Holdings Inc, Nexstar Media Group, UTI Energy, Starwood Property Trust, AMC Entertainment Holdings, Marathon Digital Holdings, IonQ Inc, Digital Turbine, Virgin Galactic Holdings , Inc, Arm Holdings plc, ARM, Ginkgo Bioworks Holdings, Suncor Energy, AppLovin Corporation, B2Gold Corp, Luminar Technologies, MGM Resorts International, MGM, Bloom Energy Corporation, Li Auto Inc, Oatly, Kopin Corp, Fiverr International, YETI Holdings, YPF S.A, Ship Lease, Himax Technologies Inc, Dickinson, CommScope Holding, RBC, Agile Therapeutics, Apyx Medical Corporation, Grab Holdings, Hawaiian Electric Industries, Profire Energy, Flags Inc, Stereotaxis Inc, TransDigm, US Foods Holding Corp, Utz Brands, Valvoline Inc, Weibo Corporation, Wix.com Ltd, Trade, Petroleo Brasileiro SA Petrobras, Growth, Aurora Cannabis Inc, Navitas Semiconductor Corp, Archer Aviation Inc, Semiconductor, Energy Fuels Corp, Illumina Inc, Spike Investment Corp, Algonquin Power & Utilities Corp, AngloGold, Central Puerto S.A, Hudson Global, AirSculpt Technologies, Partners, Soho House, Jim Cramer's Charitable, Handout, Getty Locations: U.S, Macao, Asia, China, Las, Singapore, Wynn's Vegas, Boston, United Arab Emirates, Gilead, VVV, Central, Soho

☆ FibroGen's neuromuscular disorder drug fails in late-stage study
▼ + stars: | 2023-06-07 | by ( ) www.reuters.com time to read: 1 min

June 7 (Reuters) - FibroGen Inc (FGEN.O) said on Wednesday its drug to treat a type of neuromuscular disorder failed to meet the main goal in a late-stage study, sending the company's shares down about 14% in premarket trading. The treatment was generally safe and well tolerated for patients with Duchenne muscular dystrophy (DMD). DMD is a progressive degenerative disorder that hampers muscle movement and affects one in 3,600 newborn boys, most of whom die by the age of 30. Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Sriparna Roy, Shilpi Majumdar, Shounak Organizations: FibroGen, Thomson Locations: Bengaluru

☆ Here are Friday's biggest analyst calls: Apple, Amazon, Broadcom, Bowlero, Microsoft, Rivian & more
▼ + stars: | 2023-06-02 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Friday's biggest calls on Wall Street: Bank of America reiterates Broadcom as buy Bank of America raised its price target on the stock to $950 per share from $800 after Broadcom's earnings report on Thursday. "Our new PO of $950 (from $800) represents 21x CY24E EV/FCF as AI accelerates company growth potential. Bank of America reiterates Five Below as buy Bank of America said the discount retailer has "recession resilience." Bank of America upgrades Surgery Partners to buy from neutral Bank of America said the health care company has " favorable long-term tailwinds." Bank of America reiterates Lululemon as buy Bank of America said Lululemon is a "best-in-class growth story."

Persons: it's, Riley FBR, Riley, Piper Sandler downgrades, Piper, Morgan Stanley, Apple, it's bullish, Wells, Stifel, Goldman Sachs, Goldman, 100bps, Frank Klein, Tim Fallon, Tim Bei, Derek Mulvey, RIVN, Lululemon Organizations: Bank of America, Broadcom, Warner Music, JPMorgan, Energy, Surgery Partners, of America, Partners, Amazon, Microsoft, ISI, Barclays, Strategic Finance, Citi, Frontier Citi, LaGuardia, Spirit Airlines, Watch Locations: Valvoline, Biopharma, Agriculture, Normal , IL

☆ Stocks making the biggest moves midday: Lululemon, SentinelOne, T-Mobile, MongoDB and more
▼ + stars: | 2023-06-02 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

MongoDB — Shares of the data developer rocketed 28% after the company forecast strong fiscal first-quarter earnings and boosted its full-year guidance. The company cited macroeconomic pressure as a contributor to slowing sales growth in a shareholder letter and cut its full-year revenue guidance. PagerDuty — Shares slumped 17.1% after the IT cloud company issued second-quarter revenue guidance that missed expectations. Samsara — The cloud company popped nearly 28% after reporting a smaller-than-expected first-quarter loss and lifting its full-year sales guidance. That's above the expected loss of 5 cents a share and $191.9 million in revenue, according to FactSet.

Persons: Lululemon, Amazon, MongoDB, Wall, SentinelOne, Dupont, Dupont de Nemours, Zscaler, Morgan Stanley, PagerDuty, StreetAccount, Dell, Ginkgo, Goldman Sachs, Goldman, Yun Li, Hakyung Kim, Brian Evans, Alex Harring Organizations: Wireless, Bloomberg News, Verizon, Mobile, Amazon, Dish, Broadcom —, Broadcom, Bank of America, Dupont de, DuPont, U.S . Water Systems, Stifel Locations: New York

REUTERS/Dado Ruvic/Illustration/Oct 26 (Reuters) - GSK Plc (GSK.L) came closer to securing its first drug approval since its consumer health spin-off in July as an expert panel of the U.S. health regulator backed an approval for its drug to treat anemia in some patients with chronic kidney disease (CKD). The advisers to the Food and Drug Administration on Wednesday voted 13-3 in favor of the oral drug for patients on dialysis, although GSK was expecting approval for a broader CKD population. The panel, hesitant about backing the drug for patients not on dialysis, voted 11-5 against it for that group, citing increased safety risks such as heart failure. read moreGSK's drug, daprodustat, is the first from the HIF-PH inhibitor class to win U.S. FDA panel's endorsement. The FDA, which usually follows the recommendations of its expert panel, is expected to make its final decision on the drug by Feb. 1.

Search resuls for: "FibroGen"

5 mentions found